A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 22, Issue 2, 1999, Pages 139-145

  Rakik, Abdelrahim ^a   Ait Khaled, Mounir ^a   Griffin, Philip ^a   Thomas, Deborah A ^b   Tisdale, Margaret ^a   Kleim, Jörg Peter ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Abacavir; Amino acid insertions; Amprenavir; Antiretroviral therapy; Drug resistance; Efavirenz

Indexed keywords

ABACAVIR; AMINO ACID; AMPRENAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AMINO ACID SUBSTITUTION; ARTICLE; CROSS RESISTANCE; GENE AMPLIFICATION; GENE FREQUENCY; GENE INSERTION; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0032724499     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199910010-00005     Document Type: Article

References (22)

1. Hirsch MS, Conway B, D' Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implication for clinical management. JAMA 1998;279:1984-91.
2. Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997;5:2-14.
3. Shirasaka T, Kavlick MF, Ueno T, et al. Emergence of human immunodeficiency type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxy-nucleosides. Proc Natl Acad Sci USA 1995, 92: 2398-2402.
4. Iversen AKN, Shafer RW, Wehrly K, et al. Multiple-drug resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 1996;70:1086-90.
5. De Antoni A, Foli J, Lisziewicz J, Lori F. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J Infect Dis 1997;176:899-903.
6. Tamalet C, Izopet J, Koch N, Fantini J, Yahi N. Stable rearrangements of the β3-β4 hairpin loop of HIV-1 reverse transcriptase in plasma viruses from patients receiving combination therapy. AIDS 1998;12:F161-6.
7. Winters MA, Cooley KL, Girard YA, et al. A 6-Basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 1998;102:1769-75.
8. Ross L, Johnson M, Graham N, Shaefer M, Griswold M, St Clair M. In-frame insertions and deletions in the hiv RT coding region between aa 67 and 69 are associated with a decreased patient viral load [abstract 639]. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, 1998.
9. Bloor S, Hertogs K, Desner RL, et al. Virological basis for HIV-1 resistance to stavudine investigated by analysis of clinical samples [abstract 15]. Presented at the 2nd International Workshop on Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 1998.
10. Whitcomb JM, Limoli K, Wrin T, et al. Phenotypic and genotypic analysis of stavudine-resistant isolates of HIV-1 [abstract 17]. Presented at the 2nd International Workshop on Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 1998.
11. De Jong JJ, Jurriaans S, Goudsmit J, et al. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS 1999;13:75-80.
12. Calvez V, Mouroux M, Yvon A, et al. Zidovudine resistance associated mutations can be selected in patients receiving long-term exposure to stavudine [abstract 38]. Presented at the 3rd International Workshop on Drug Resistance and Treatment Strategies, San Diego, 1999.
13. Race E, Ferchal F, Dam E et al. Extended HIV-1 cross-resistance to nucleoside analogues and non-nucleoside reverse transcriptase inhibitors following low-level escape to nucleoside analogue treatment [abstract 18]. Presented at the 3rd International Workshop on Drug Resistance and Treatment Strategies, San Diego, 1999.
14. Ross L, Danehower S, Johnson M et al. D4T based combination and monotherapy select for "ZDV" resistance HIV-1 mutations in ZDV naïve adult and in pediatric patients [abstract 15]. Presented at the 3rd International Workshop on Drug Resistance and Treatment Strategies, San Diego, 1999.
15. Mulder J, Resnick R, Saget B, Scheibel S, Herman S, Payne H, Harrigan P.R, & Kwok S. A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma with enhanced sensitivity. J Clin Microbiol 1997;35:1278-80.
16. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, Henfrey RD. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993;14;365:671-3.
17. Hertogs K, Bethune M, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998;42:269-76.
18. Larder BA, Bloor S, Hertogs K, Van den Eynde, Pauwels R. HIV-1 Gag cleavage site changes are associated with specific protease mutations in plasma HIV-1 RNA but are not always retained in replication-competent, protease inhibitor-resistant recombinant viruses [abstract 23]. Presented at the 2nd International Workshop on Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 1998.
19. Arion D, Kaushik N, Mc Cormick S, et al. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (zidovudine) [abstract 14]. Presented at the 2nd International Workshop on Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 1998.
20. Tantillo C, Ding J, Jacobo-Molina A, et al. Location of anti-AIDS drug binding sites and resistance mutations in the three dimensional structure of HIV-1 RT, J Mol Biol 1994;243:369-87.
21. Boyer PL, Tantillo C, Jacobo-Molina A, et al. Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. Proc Natl Acad Sci USA 1994;91: 4882-6.
22. Huang H, Chopra R, Verdine GL, Harrison SC. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implication for drug resistance. Science 1998;282:1669-75.